Reducing inflammation in COPD: The evidence builds

Thorax

Volumn 62, Issue 11, 2007, Pages 927-928

  Barnes, Neil ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; STEROID;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; LUNG LAVAGE; MONOTHERAPY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

EVIDENCE-BASED MEDICINE; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 36048940783     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.082677     Document Type: Editorial

References (17)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. Bethesda: National Heart Lung and Blood Institute, 2006.
2. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airways obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
3. 1. Am J Respir Crit Care Med 1997;155:852-7.
4. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-7.
5. 1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71.
6. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 1997;155:449-53.
7. Keatings VS, Jatakanon A, Wordsdell YM, et al. Effects of inhaled and oral glucorticosteroids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
8. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-6.
9. Gizycki MJ, Hattotuwa KL, Barnes N, et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799- 803.
10. Verhoeven GT, Hegmans JP, Mulder PG, et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002;57:694-700.
11. Barnes NC, Qiu Y-S, Pavord ID, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-43.
12. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-43.
13. Calverley P, Pauwels R, Vestbo J, et al. Combining salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Lancet 2003;361:1449-56.
14. Mahlet DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
15. Szafranski W, Cukier A, Ramirez R, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
16. Calverley PMA, Anderson JA, Celli B, for the TORCH investigators, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
17. Gamble E, Grootendorst D, Brightling E, et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-82.